Genmab A/S (OTCMKTS:GNMSF – Get Free Report) shares hit a new 52-week high during trading on Monday. The company traded as high as $355.00 and last traded at $355.00, with a volume of 14 shares traded. The stock had previously closed at $353.00.
Genmab A/S Price Performance
The business has a fifty day moving average price of $329.96 and a 200 day moving average price of $288.98. The company has a market capitalization of $23.15 billion, a price-to-earnings ratio of 29.49 and a beta of 0.75. The company has a debt-to-equity ratio of 0.81, a current ratio of 2.46 and a quick ratio of 2.44.
About Genmab A/S
Genmab A/S is a Danish biotechnology company focused on discovering, developing and commercializing differentiated antibody-based medicines for the treatment of cancer and other serious diseases. The company develops therapeutic antibodies and antibody formats designed to engage the immune system, target disease-specific biology and potentially improve treatment outcomes.
Genmab’s technology platforms include DuoBody, which enables the development of bispecific antibodies, as well as HexaBody and other antibody-engineering technologies.
Further Reading
- Five stocks we like better than Genmab A/S
- Constellation Energy’s Google Deal Shows Why Nuclear Uprates Matter for AI
- Lamb Weston’s Turnaround Is Starting to Look Real
- These 3 Stocks Got the Most Love From Analysts in September
- Record French Debt Could Create Opportunities for U.S. Market Operators
Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.
